Pioneer SCA3 Translational Research Award
The Pioneer SCA3 Translational Research Award funds innovative research to advance treatment, understanding, and care for Spinocerebellar Ataxia Type 3, emphasizing translational and clinical impact.
Funder: National Ataxia Foundation
Due Dates (Anticipated): August 2026 (Letter of Intent) | December 2026 (Full application)
Funding Amounts: Up to $100,000 for a 1-year project; no indirect costs allowed; max 50% of budget for personnel.
Summary: Funds innovative research to advance treatment, understanding, and care for Spinocerebellar Ataxia Type 3 with a focus on translational and clinical impact.
Key Information: Forecasted cycle—dates and details subject to change; check program page for updates.
Description
The Pioneer SCA3 Translational Research Award, offered by the National Ataxia Foundation, is an annual grant supporting independent researchers working to advance treatment and care for individuals with Spinocerebellar Ataxia Type 3 (SCA3). The program prioritizes preclinical, translational, or clinical research projects with a direct and significant impact on SCA3 patient outcomes. Areas of emphasis include therapeutic development, biomarker discovery, clinical trial readiness, mechanistic research, and care optimization. Proposals should demonstrate a clear path toward improving clinical solutions and patient quality of life, leveraging innovative approaches and interdisciplinary collaboration.
